Literature DB >> 26304912

Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.

Aziz Nazha1, Joseph D Khoury2, Raajit K Rampal2, Naval Daver2.   

Abstract

Primary myelofibrosis is a stem cell-derived clonal malignancy characterized by unchecked proliferation of myeloid cells, resulting in bone marrow fibrosis, osteosclerosis, and pathologic angiogenesis. Bone marrow fibrosis (BMF) plays a central role in the pathophysiology of the disease. This review describes current issues regarding BMF in primary myelofibrosis, including the pathophysiology and impact of abnormal deposition of excess collagen and reticulin fibers in bone marrow spaces, the modified Bauermeister and the European Consensus grading systems of BMF, and the prognostic impact of BMF on the overall outcome of patients with primary myelofibrosis. The impact of novel therapeutic strategies, including JAK-STAT inhibitors and allogeneic stem cell transplant, on BMF is discussed. ©AlphaMed Press.

Entities:  

Keywords:  Bone marrow fibrosis; Collagen fibrosis; Primary myelofibrosis; Reticulin fibrosis

Mesh:

Substances:

Year:  2015        PMID: 26304912      PMCID: PMC4591957          DOI: 10.1634/theoncologist.2015-0094

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  65 in total

1.  Evaluation of stroma in human immunodeficiency virus/acquired immunodeficiency syndrome-affected bone marrows and correlation with CD4 counts.

Authors:  Dennis P O'Malley; Joy Sen; Beth E Juliar; Attilio Orazi
Journal:  Arch Pathol Lab Med       Date:  2005-09       Impact factor: 5.534

2.  New onset of myelofibrosis in association with pulmonary arterial hypertension.

Authors:  Uday Popat; Adaani Frost; Enli Liu; Romelia May; Remzi Bag; Vishnu Reddy; Josef T Prchal
Journal:  Ann Intern Med       Date:  2005-09-20       Impact factor: 25.391

3.  Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.

Authors:  J Thiele; H M Kvasnicka; H Dietrich; G Stein; M Hann; A Kaminski; N Rathjen; K A Metz; D W Beelen; M Ditschkowski; A Zander; N Kroeger
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

Review 4.  Pathogenesis of myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

5.  Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis.

Authors:  M C Martyré; M C Le Bousse-Kerdiles; N Romquin; S Chevillard; V Praloran; J L Demory; B Dupriez
Journal:  Br J Haematol       Date:  1997-05       Impact factor: 6.998

Review 6.  New insights into the pathogenesis and drug treatment of myelofibrosis.

Authors:  Ayalew Tefferi
Journal:  Curr Opin Hematol       Date:  2006-03       Impact factor: 3.284

7.  The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats.

Authors:  M Yanagida; Y Ide; A Imai; M Toriyama; T Aoki; K Harada; H Izumi; H Uzumaki; M Kusaka; T Tokiwa
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

8.  Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders.

Authors:  Vonda K Douglas; Martin S Tallman; Larry D Cripe; LoAnn C Peterson
Journal:  Am J Clin Pathol       Date:  2002-06       Impact factor: 2.493

9.  Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases.

Authors:  Mingjiang Xu; Edward Bruno; Joseph Chao; Stephen Huang; Guido Finazzi; Steven M Fruchtman; Uday Popat; Josef T Prchal; Giovanni Barosi; Ronald Hoffman
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

10.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

View more
  4 in total

1.  Captopril mitigates splenomegaly and myelofibrosis in the Gata1low murine model of myelofibrosis.

Authors:  Seth J Corey; Jyoti Jha; Elizabeth A McCart; William B Rittase; Jeffy George; Joseph J Mattapallil; Hrishikesh Mehta; Mungunsukh Ognoon; Michelle A Bylicky; Thomas A Summers; Regina M Day
Journal:  J Cell Mol Med       Date:  2018-07-04       Impact factor: 5.310

Review 2.  Focus on Osteosclerotic Progression in Primary Myelofibrosis.

Authors:  Mariarita Spampinato; Cesarina Giallongo; Alessandra Romano; Lucia Longhitano; Enrico La Spina; Roberto Avola; Grazia Scandura; Ilaria Dulcamare; Vincenzo Bramanti; Michelino Di Rosa; Nunzio Vicario; Rosalba Parenti; Giovanni Li Volti; Daniele Tibullo; Giuseppe A Palumbo
Journal:  Biomolecules       Date:  2021-01-19

3.  Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?

Authors:  Xun Lai; Yun Yan Sun; Lung Ji Chang; Yu Ru Ma; Xue Zhong Gu; Xiang Mei Yao; Bo Nie; Yan Wen; Xue Mei Zhang; Ya Xian Jiang; Hui Yang; Li Qun Yu; Ming Jing Fang; Ling Wang; Xue Yuan Bo
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

4.  Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis.

Authors:  Monika Dadrich; Nils H Nicolay; Paul Flechsig; Sebastian Bickelhaupt; Line Hoeltgen; Falk Roeder; Kai Hauser; Alexandra Tietz; Jürgen Jenne; Ramon Lopez; Manuel Roehrich; Ute Wirkner; Michael Lahn; Peter E Huber
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.